



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

February 10, 2026

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Press Release- Unaudited Financial Results for the Quarter and Nine Months ended December 31, 2025.

The Board of Directors of the Company at their Meeting held on February 09, 2026, has inter alia, considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2025.

Please find attached the Press Release regarding the Unaudited Financial Results of the Company for the Quarter and Nine Months ended December 31, 2025.

Kindly take the same on record.

Thanking you,

For Supriya Lifescience Limited

Prachi Sathe
Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website:
www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.- Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE



SUPRIYA LIFESCIENCE LTD.

Press Release for immediate distribution

Supriya Lifescience Delivers Strong Q3 FY26 Results with 11% YoY Revenue Growth

Mumbai, 10th February 2026: The unaudited financial statements for Q3FY26 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 120 countries across the globe.

Key Consolidated Financial Highlights:

Particulars	Q3 FY26	Q3 FY25
Revenues (in Rs Cr)	206.44	185.65
EBITDA (in Rs Cr)	72.08	65.96
EBITDA Margin	34.9%	35.5%
PAT (in RsCr)	49.68	46.78
PAT Margin	24.1%	25.2%
Quarterly EPS (in Rs)	6.2	5.8

Key Highlights for Q3 FY26:

In Q3 FY26, Supriya Lifescience Ltd. witnessed a 11.2 % year-over-year growth in Revenue to Rs 206.44 crore compared to Rs 185.65 crore in Q3 FY25.

EBITDA for Q3 FY26 stood at Rs 72.08 crore, with an EBITDA margin of 34.9%, as against Rs 65.96 crore in Q3 FY25 with a margin of 35.5%.

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25.

The PAT Margin stood at 24.1% in Q3 FY26 versus 25.2% in Q3 FY25.

The anesthetic segment emerged as the primary growth driver in 9M FY26, contributing 54% of total revenues, compared to 48% in 9M FY25. The vitamins segment also witnessed improved traction, with its contribution increasing from 11% to 12% during the same period.

Growth was driven by Latin American market. Contribution of LatAm markets grew to 24% from 21% while the share of North America in the business mix went up to 6% in Q3FY26 from 3% over the last two quarters. However, Europe continues to be the Company's largest market, accounting for 36% of business revenues in Q3 FY26 followed by Asia at 32%.

Capacity utilisation improved significantly, recovering from 70% in FY25 to 76% in 9MFY26. To support future growth across business segments, the Company has acquired three land parcels located near its existing manufacturing facilities, strengthening its long-term expansion plans.

Mr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd., commenting on the results, said, *“Our performance this quarter reflects consistent execution and sustained profitability, supported by steady demand across key global markets. Exports continued to remain a strong contributor, accounting for approximately 82% of revenues in Q3, with Europe forming a significant share of the business mix. Capacity utilisation improved to around 76% during 9MFY26, aided by the ramp-up of Module E at our Lote Parshuram facility, enhancing operational efficiency and supply reliability. As we prepare for the commercial launch of our Ambernath formulation facility in Q4 FY26 and continue to deepen our presence in regulated markets through backward integration and new product introductions, we remain confident of driving stronger growth in the coming quarters.”*

Disclaimer Statements in this “Document” describing the company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

About Supriya Lifescience Ltd.:

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our state-of-the-art facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities USFDA, EDQM, WHO, PMDA, KFDA and ANVISA are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

For more details, contact:

Abhishek Chawande: Abhishek.Chawande@dentsu.com | 9664516774

Sanjukta Ghadge: Sanjukta.ghadge@dentsu.com | 98926 89895